Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting
Second abstract with data concluding vibegron does not inhibit CYP2D6, a common drug metabolism pathway, also accepted for podium presentation
The late-breaker presentation of the vibegron international Phase 3 pivotal trial EMPOWUR by Dr.
|International Phase 3, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder. EMPOWUR|
|Next Frontier Plenary Session, Sunday Afternoon|
|Sunday, May 5, 2019 at 1:10 - 1:19 p.m. CT|
|Location: MCP: W375d|
|Presenter: David Staskin, MD, Tufts University School of Medicine, Boston|
|Once-Daily Vibegron, a Novel Oral β3 Agonist Does Not Inhibit CYP2D6, a Common Pathway for Drug Metabolism in Patients on OAB Medications|
|Friday, May 3, 2019 at 1:00 - 1:10 p.m. CT|
|Location: MCP: W179b|
Presenter: Matthew Rutman, MD, Columbia University College of Physicians and Surgeons, New York
Presentation abstracts may be found on the AUA website at http://www.aua2019.org/abstracts. Additional information about the presentations remain subject to the AUA embargo policy and will be made available at the time of the presentations.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company’s intent, belief or expectations and can be identified by words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “to be,” “will,” “would,” or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. In this press release, forward-looking statements include, but are not limited to, statements regarding the Company’s plans and strategies for the development and commercialization of innovative therapies, including vibegron, for the treatment of urological conditions.
The Company’s forward-looking statements are based on management’s current expectations and beliefs, and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those projected, forecasted or expected. Although the Company believes that the assumptions underlying these forward-looking statements are reasonable, they are not guarantees and the Company can give no assurance that its expectations will be attained. Factors that could materially affect the Company’s operations and future prospects or which could cause actual results to differ materially from expectations include, but are not limited to the risks and uncertainties listed in the Company’s filings with the
Investor inquiries: Investors@Urovant.com
Media inquiries: Media@Urovant.com